Sponsor or institution

Clinical trials and research at The United Bio-Technology (Hengqin) Co., Ltd.

• 7Clinical trials
• 1New in 30 days
• 1Country

Newest trials

All recruiting trials (7)

• UBT37034 Injection safety study in adults with overweight or obesity

  This study tests different doses of UBT37034 injections to see if they are safe and tolerable in adults who are overweight or have obesity.

  Recruiting Phase 1 The United Bio-Technology (Hengqin) Co., Ltd. · Changsha, Hunan · NCT07873645

• Drug Interaction Test of UBT251 Injection in People with Overweight or Obesity

  This study tests whether injecting UBT251 affects how metformin, warfarin, atorvastatin, or digoxin behave in the body for adults with overweight or obesity.

  Recruiting Phase 1 The United Bio-Technology (Hengqin) Co., Ltd. · Hefei, Anhui · NCT07785934

• 3-Arm UBT251 Injection for Type 2 Diabetes Not Controlled by Diet and Exercise

  This Phase 3 trial tests different doses of UBT251 injections versus placebo to see if it helps adults with type 2 diabetes whose blood sugar remains above target despite diet and exercise.

  Recruiting Phase 3 The United Bio-Technology (Hengqin) Co., Ltd. · Changsha, Hunan · NCT07659574

• UBT251 Injection vs Semaglutide for type 2 diabetes with inadequate control on metformin

  This study tests whether UBT251 injections (2, 4, or 6 mg) can control blood sugar as well as or better than semaglutide in adults with type 2 diabetes not adequately controlled on metformin ± sulfonylurea or SGLT2 inhibitors.

  Recruiting Phase 3 The United Bio-Technology (Hengqin) Co., Ltd. · Shanghai · NCT07653477

• Single-dose subcutaneous UBT38006 in healthy adult males

  This early study tests if a single dose of UBT38006 is safe and tolerated in healthy adult men and compares its blood levels and effects to insulin products.

  Recruiting Phase 1 The United Bio-Technology (Hengqin) Co., Ltd. · Hefei, Anhui · NCT07630233

• UBT251 treatment for metabolic dysfunction-associated steatohepatitis (MASH)

  This trial will test whether daily UBT251 (2 mg, 4 mg, or 6 mg) for 48 weeks helps adults with biopsy-confirmed MASH and moderate fibrosis compared with placebo.

  Recruiting Phase 2 The United Bio-Technology (Hengqin) Co., Ltd. · Beijing, Beijing Municipality · NCT07145151

• UBT251 injection for adults with overweight or obesity and chronic kidney disease

  This randomized, double-blind trial will test whether UBT251 injections help obese or overweight adults with chronic kidney disease.

  Recruiting Phase 2 The United Bio-Technology (Hengqin) Co., Ltd. · Beijing · NCT07134335

Quick answers

How many clinical trials run by The United Bio-Technology (Hengqin) Co., Ltd. are recruiting right now?

7, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →